PT -期刊文章盟Buhl罗兰AU - Maltais,弗朗索瓦盟——亚伯拉罕,罗杰盟——Bjermer列夫盟——Derom Eric AU -弗格森,加里•盟——通过žar MatjažAU -赫伯特,雅克盟——McGarvey Lorcan盟——Pizzichini埃米利奥盟-里德,吉姆AU - Veale,安东尼AU -格朗克,Lars AU -汉密尔顿,艾伦•AU - Korducki劳伦斯盟泰兹拉夫-。Kay AU - Waitere-Wijker, Stella AU - Watz, Henrik AU - Bateman，埃里克TI - Tiotropium和olodaterol固定剂量组合< em >和< / em > mono-components在慢性阻塞性肺病(黄金2 - 4)援助- DP - 2015年4月01 TA - 10.1183/09031936.00136014欧洲呼吸杂志》第六PG - 969 - 979 - 45 IP - 4 4099 - //www.qdcxjkg.com/content/45/4/969.short 4100 - //www.qdcxjkg.com/content/45/4/969.full和欧元J2015 Apr 01; 45 AB - Efficacy and safety of tiotropium+olodaterol fixed-dose combination (FDC) compared with the mono-components was evaluated in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in two replicate, randomised, double-blind, parallel-group, multicentre, phase III trials. Patients received tiotropium+olodaterol FDC 2.5/5 μg or 5/5 μg, tiotropium 2.5 μg or 5 μg, or olodaterol 5 μg delivered once-daily via Respimat inhaler over 52 weeks. Primary end points were forced expiratory volume in 1 s (FEV1) area under the curve from 0 to 3 h (AUC0–3) response, trough FEV1 response and St George's Respiratory Questionnaire (SGRQ) total score at 24 weeks. In total, 5162 patients (2624 in Study 1237.5 and 2538 in Study 1237.6) received treatment. Both FDCs significantly improved FEV1 AUC0–3 and trough FEV1 response versus the mono-components in both studies. Statistically significant improvements in SGRQ total score versus the mono-components were only seen for tiotropium+olodaterol FDC 5/5 μg. Incidence of adverse events was comparable between the FDCs and the mono-components. These studies demonstrated significant improvements in lung function and health-related quality of life with once-daily tiotropium+olodaterol FDC versus mono-components over 1 year in patients with moderate to very severe COPD. Lung function/symptomatic benefits of daily tiotropium+olodaterol fixed-dose combination in moderate-very severe COPD http://ow.ly/DIKiY